1-8 of 8
Pranav Abraham
Close
Sort by
Journal Articles

The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response

John Mascarenhas, Claire Harrison, Tammy Schuler, Djibril Liassou, Marné Garretson, Sankar Mahadevan, Ali McBride, Derek Tang, Irene S. DeGutis, Pranav Abraham, Aaron T. Gerds
Journal: Blood
Blood (2022) 140 (Supplement 1): 5276–5278.
https://doi.org/10.1182/blood-2022-156780
Published: 2022
Journal Articles

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Claire N. Harrison, John Mascarenhas, Pranav Abraham, Arianna Kee, Jose Alberto Nadal, Alexandrina Balanean, Ali McBride, Jonathan K. Kish, Djibril Liassou, Bruce A. Feinberg, Aaron T. Gerds
Journal: Blood
Blood (2021) 138 (Supplement 1): 3059.
https://doi.org/10.1182/blood-2021-145569
Published: 2021
Journal Articles

Real-World Outcomes with Fedratinib Therapy in Patients Who Discontinued Ruxolitinib for Primary Myelofibrosis

Francesco Passamonti, Quynh Do, Youbei Lou, Manoj Chevli, Pranav Abraham
Journal: Blood
Blood (2021) 138 (Supplement 1): 3645.
https://doi.org/10.1182/blood-2021-148188
Published: 2021
Journal Articles

Comparative Effectiveness of Fedratinib and Pacritinib for the Treatment of Myelofibrosis in Patients with Low Platelet Counts: A Simulated Treatment Comparison Study

Patrick Daniele, Pranav Abraham, Arianna Kee, Gabriel Tremblay, Shelonitda Rose, Ali McBride
Journal: Blood
Blood (2021) 138 (Supplement 1): 5034.
https://doi.org/10.1182/blood-2021-145685
Published: 2021
Journal Articles

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

John Mascarenhas, Aaron T. Gerds, Arianna Kee, Jonathan K. Kish, Pranav Abraham, Alexandrina Balanean, Jose Alberto Nadal, Djibril Liassou, Bruce A. Feinberg, Ali McBride, Claire N. Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 1980.
https://doi.org/10.1182/blood-2021-145573
Published: 2021
Journal Articles

Indirect Treatment Comparisons of the Effect of Fedratinib Versus Navitoclax Plus Ruxolitinib on Spleen Volume and Symptoms in Patients with Myelofibrosis and Prior Ruxolitinib Treatment

Pranav Abraham, Xiaomeng Liao, Manoj Chevli, Sarah Smith
Journal: Blood
Blood (2021) 138 (Supplement 1): 4626.
https://doi.org/10.1182/blood-2021-145862
Published: 2021
Journal Articles

Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review

Francesco Passamonti, Florian H. Heidel, MD, Rohan C. Parikh, Derek Tang, Betsy J. Lahue, Jose Alberto Nadal, Keith L. Davis, Mayank Ajmera, Arianna Kee, Pranav Abraham
Journal: Blood
Blood (2020) 136 (Supplement 1): 23.
https://doi.org/10.1182/blood-2020-136673
Published: 2020
Journal Articles

Real-World Investigation of Spleen, Symptom, and Hematologic Response in Patients with Myelofibrosis Treated with First-Line Ruxolitinib

Jonathan K. Kish, PhD MPH, Arianna Kee, Pranav Abraham, Ronda Copher, PhD, Talia Miller, Aaron T. Gerds, MDMS
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-136656
Published: 2020